Annual SG&A
$5.23 M
-$1.47 M-21.92%
31 December 2023
Summary:
Enlivex Therapeutics annual selling, general & administrative expenses is currently $5.23 million, with the most recent change of -$1.47 million (-21.92%) on 31 December 2023. During the last 3 years, it has risen by +$1.63 million (+45.28%). ENLV annual SG&A is now -25.08% below its all-time high of $6.99 million, reached on 31 December 2016.ENLV Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$987.00 K
-$106.00 K-9.70%
30 June 2024
Summary:
Enlivex Therapeutics quarterly selling, general & administrative expenses is currently $987.00 thousand, with the most recent change of -$106.00 thousand (-9.70%) on 30 June 2024. Over the past year, it has dropped by -$292.00 thousand (-22.83%). ENLV quarterly SG&A is now -62.53% below its all-time high of $2.63 million, reached on 31 March 2016.ENLV Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$450.65 M
-$22.29 M-5.20%
30 June 2024
Summary:
Enlivex Therapeutics TTM selling, general & administrative expenses is currently -$450.65 million, with the most recent change of -$22.29 million (-5.20%) on 30 June 2024. Over the past year, it has dropped by -$456.90 million (-7318.53%). ENLV TTM SG&A is now -32089.50% below its all-time high of $8.41 million, reached on 30 June 2016.ENLV TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENLV Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | -22.8% | -7318.5% |
| 3 y3 years | +45.3% | -16.7% | -9268.9% |
| 5 y5 years | +339.8% | +81.1% | -10000.0% |
ENLV Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -21.9% | +45.3% | -60.2% | +34.6% | -166.3% | at low |
| 5 y | 5 years | -21.9% | +339.8% | -60.2% | +81.1% | -474.3% | at low |
| alltime | all time | -25.1% | +5984.9% | -62.5% | +139.5% | <-9999.0% | at low |
Enlivex Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $987.00 K(-9.7%) | $4.09 M(-13.3%) |
| Mar 2024 | - | $1.09 M(+49.1%) | $4.72 M(-9.8%) |
| Dec 2023 | $5.23 M(-21.9%) | $733.00 K(-42.7%) | $5.23 M(-16.2%) |
| Sept 2023 | - | $1.28 M(-20.8%) | $6.24 M(-3.1%) |
| June 2023 | - | $1.61 M(+0.4%) | $6.44 M(-2.2%) |
| Mar 2023 | - | $1.61 M(-7.8%) | $6.59 M(-1.7%) |
| Dec 2022 | $6.70 M(+7.4%) | $1.74 M(+18.1%) | $6.70 M(-9.9%) |
| Sept 2022 | - | $1.48 M(-16.2%) | $7.44 M(+4.1%) |
| June 2022 | - | $1.76 M(+2.3%) | $7.15 M(+7.4%) |
| Mar 2022 | - | $1.72 M(-30.6%) | $6.66 M(+6.7%) |
| Dec 2021 | $6.24 M(+73.2%) | $2.48 M(+109.4%) | $6.24 M(+27.0%) |
| Sept 2021 | - | $1.19 M(-6.6%) | $4.92 M(+7.6%) |
| June 2021 | - | $1.27 M(-2.8%) | $4.57 M(+6.9%) |
| Mar 2021 | - | $1.30 M(+12.9%) | $4.27 M(+18.7%) |
| Dec 2020 | $3.60 M(+25.5%) | $1.16 M(+38.1%) | $3.60 M(+6.4%) |
| Sept 2020 | - | $837.00 K(-14.2%) | $3.39 M(+9.4%) |
| June 2020 | - | $976.00 K(+54.2%) | $3.09 M(+13.8%) |
| Mar 2020 | - | $633.00 K(-32.7%) | $2.72 M(-5.3%) |
| Dec 2019 | $2.87 M(+141.2%) | $940.00 K(+72.5%) | $2.87 M(+13.9%) |
| Sept 2019 | - | $545.00 K(-9.3%) | $2.52 M(+16.1%) |
| June 2019 | - | $601.00 K(-23.3%) | $2.17 M(+24.1%) |
| Mar 2019 | - | $784.00 K(+32.9%) | $1.75 M(+47.1%) |
| Dec 2018 | $1.19 M(+156.5%) | $590.00 K(+201.0%) | $1.19 M(-162.7%) |
| Sept 2018 | - | $196.00 K(+8.9%) | -$1.90 M(+31.8%) |
| June 2018 | - | $180.00 K(-19.6%) | -$1.44 M(+68.9%) |
| Mar 2018 | - | $224.00 K(-109.0%) | -$853.00 K(-283.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $464.00 K(-93.4%) | -$2.50 M(-482.1%) | $464.00 K(-89.1%) |
| Sept 2017 | - | $654.00 K(-14.8%) | $4.25 M(-12.9%) |
| June 2017 | - | $768.00 K(-50.2%) | $4.87 M(-17.3%) |
| Mar 2017 | - | $1.54 M(+20.1%) | $5.89 M(-15.6%) |
| Dec 2016 | $6.99 M(+0.5%) | $1.28 M(+0.2%) | $6.99 M(-10.7%) |
| Sept 2016 | - | $1.28 M(-28.3%) | $7.82 M(-7.0%) |
| June 2016 | - | $1.79 M(-32.2%) | $8.41 M(+2.3%) |
| Mar 2016 | - | $2.63 M(+24.4%) | $8.22 M(+18.2%) |
| Dec 2015 | $6.95 M(+163.5%) | $2.12 M(+13.0%) | $6.95 M(+16.2%) |
| Sept 2015 | - | $1.87 M(+17.4%) | $5.99 M(+19.5%) |
| June 2015 | - | $1.60 M(+16.8%) | $5.01 M(+31.7%) |
| Mar 2015 | - | $1.37 M(+18.8%) | $3.81 M(+44.2%) |
| Dec 2014 | $2.64 M(+534.4%) | $1.15 M(+27.9%) | $2.64 M(+51.3%) |
| Sept 2014 | - | $899.00 K(+129.9%) | $1.74 M(+93.8%) |
| June 2014 | - | $391.00 K(+96.5%) | $900.00 K(+51.3%) |
| Mar 2014 | - | $199.00 K(-22.0%) | $595.00 K(+50.3%) |
| Dec 2013 | $416.00 K(+383.7%) | $255.00 K(+363.6%) | $396.00 K(+180.9%) |
| Sept 2013 | - | $55.00 K(-36.0%) | $141.00 K(+64.0%) |
| June 2013 | - | $86.00 K | $86.00 K |
| Dec 2012 | $86.00 K(-92.1%) | - | - |
| Dec 2002 | $1.09 M(-38.1%) | - | - |
| Dec 2001 | $1.76 M(+30.5%) | - | - |
| Dec 2000 | $1.35 M(+192.3%) | - | - |
| Dec 1999 | $460.80 K(-41.0%) | - | - |
| Dec 1998 | $781.40 K(-43.6%) | - | - |
| Dec 1997 | $1.39 M | - | - |
FAQ
- What is Enlivex Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual SG&A year-on-year change?
- What is Enlivex Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly SG&A year-on-year change?
- What is Enlivex Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM SG&A year-on-year change?
What is Enlivex Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ENLV is $5.23 M
What is the all time high annual SG&A for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual selling, general & administrative expenses is $6.99 M
What is Enlivex Therapeutics annual SG&A year-on-year change?
Over the past year, ENLV annual selling, general & administrative expenses has changed by -$1.47 M (-21.92%)
What is Enlivex Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ENLV is $987.00 K
What is the all time high quarterly SG&A for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly selling, general & administrative expenses is $2.63 M
What is Enlivex Therapeutics quarterly SG&A year-on-year change?
Over the past year, ENLV quarterly selling, general & administrative expenses has changed by -$292.00 K (-22.83%)
What is Enlivex Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ENLV is -$450.65 M
What is the all time high TTM SG&A for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM selling, general & administrative expenses is $8.41 M
What is Enlivex Therapeutics TTM SG&A year-on-year change?
Over the past year, ENLV TTM selling, general & administrative expenses has changed by -$456.90 M (-7318.53%)